PuraPharm Corporation Limited provided consolidated earnings guidance for the six months period ended 30 June 2018. The board of directors of the Company informed the shareholders of the Company and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2018 and other information currently available to the Board, it is expected that both of the Group's revenue and profit for the six months period ended 30 June 2018 will record an increase of more than 30%, as compared with the overall revenue and profit of the Group during the corresponding period in 2017. The increase in profit was primarily attributable to (i) an increase in fair value gain on the Group's biological assets as compared to the corresponding period ended 30 June 2017 based on a valuation of the biological assets as of 30 June 2018, (ii) an increase in the profit contribution from China CCMG segment as compared to the corresponding period ended 30 June 2017, and (iii) profit contributed by the newly acquired subsidiaries in 2017. The increase in revenue was mainly attributable to: (i) an increase in sales of the Group's China Concentrated Chinese Medicine Granules (CCMG) segment resulted from the increase in sales quantity to the Group's distributors. During the six month period ended 30 June 2018, the Group continued to devote more selling and distribution expenses to strengthen the promotion of the Group's products and brands in China, as a result, more new customers were developed and the sales to the Group's existing customers continued to growth. (ii) the results of the newly acquired subsidiaries in 2017 were fully consolidated in the Group's result for the six month period ended 30 June 2018, in which only a few months results since the completion of the acquisitions were consolidated in the Group's result for the during the corresponding period in 2017.